Category Archives: Utah’s Life Sciences Companies
Attostat is now EVŌQ Nano – Seeks Next Round of Investment Following Antimicrobial Efficacy Studies
Attostat is now EVŌQ Nano! The Utah start-up has a new name, a clean look and a fresh website. Following years of scientific research and development, EVŌQ Nano is ready to share its story of next-generation nanotechnology and raise its next round of investment. “We truly are a thought leader in nanotechnology,” said CEO Scott […]
Novel Embolic Device Used for Arterial and Venous Tumor Treatments
Fluidx Medical Technology has announced successful patient use of the GPX Embolic Device to therapeutically devascularize, or block blood supply to, a tumor. The GPX Embolic Device is an innovative embolic designed to combine the benefits of other embolics like coils, particles, and liquids with simplified preparation, delivery, precision, and control leading to durable, long-term […]
MAYOR ERIN MENDENHALL’S SALT LAKE CITY 2021 PLAN INCLUDES BIOHIVE
Last week, Salt Lake City (SLC) Mayor Erin Mendenhall gave her second State of the City address – a live broadcast from the City Council Chambers in which she reflected on 2020 and outlined her plan for the City in 2021. The Mayor noted that “we are striving to make our city better through change; […]
Spectrum Solutions Collaborates with UCLA on Saliva-Based Next-Gen Sequencing (NGS) Liquid Biopsy Research for the Early Detection of Lung Cancer
Spectrum Solutions, LLC on January 27 announced it is sponsoring research in collaboration with the UCLA School of Dentistry for a study on using saliva in early lung cancer detection and analysis. Spectrum has funded a study that aims to recruit 50 patients with lung cancer and seeks to validate saliva’s tumor-specific ctDNA detection sensitivity […]
Control Medical Technology Announces New Device Removes Large Blood Clots in 1st Deep Vein Thrombosis (DVT) Patient Use
Control Medical Technology today announced the FDA cleared Control 11F Mechanical Thrombectomy system was used to remove large blood clots from patients with deep vein thrombosis (DVT). The system is Utah born, designed, engineered, patent prosecuted, and manufactured. “The Control 11 French Mechanical Thrombectomy System can remove large clots,” said Shawn Fojtik, President of Control […]
SDP Oncology Announces First Patient Dosed in Phase 1/2 Study of TP-0184 for the Treatment of Anemia in Patients with Low or Intermediate Risk Myelodysplastic Syndromes
Lehi-based Sumitomo Dainippon Pharma Oncology (SDP Oncology) recently announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS). “The management of […]
Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products
Based on its preliminary internal financial reporting for the fourth quarter 2020, Co-Diagnostics has announced that unaudited quarterly revenue for the company is anticipated to be the highest in the company’s history and to surpass analyst estimates. Analysts’ estimates for the fourth quarter ranged from $24 million to $25.98 million. Quarterly revenue is anticipated to […]
Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited; Provides Corporate Update
Clene Nanomedicine, Inc. (Clene) last week announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”) and provided a corporate update. Proceeds from this transaction totaled approximately $31.9 million. The combined, publicly traded company is operating under the name Clene Inc., and its common stock began trading on the NASDAQ Capital Market on […]
Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita
Kidney care innovators Renalytix AI and DaVita are partnering on a new program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). This first of its kind program is expected to improve patient outcomes and provide meaningful cost reductions for healthcare providers and […]
Co-Diagnostics Designs Test to Detect Mutations for New Coronavirus Strain Using CoPrimer™ Platform
Co-Diagnostics has announced that it has completed principal design work for a PCR test that would allow researchers to identify certain mutations in a newly detected variant of SARS-CoV-2 known as VUI 202012/01. The new coronavirus strain comprises several mutations and may be more contagious than its predecessors. London and the southeast of Great Britain […]
Vertex Announces FDA Approvals for Expanded Use of Cystic Fibrosis Medicines
Vertex has announced FDA approval of eligibility for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to include people with cystic fibrosis (CF) ages 12 years and older with certain mutations in the CFTR gene. SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) also received approvals to include additional responsive mutations in people with CF ages 6 years and older and age 4 […]
Phoenix PharmaLabs Announces New Investment Offering with Netcapital
Phoenix PharmaLabs (Phoenix), a Utah company developing potent, non-addictive treatments for pain and opioid and cocaine addictions, announced it has launched its second offering campaign on the Netcapital platform. This new offering follows a fund raise in 2019 of more than $1.1 million via Netcapital. Proceeds from this latest campaign will further support the development […]
